Recent Updates — IBIO
At its October 14, 2026 Annual Meeting, iBio, Inc. stockholders approved an amendment to the Certificate of Incorporation to increase the number of authorized common shares from 275 million to 500 million. The filing also notes approval of Amendment No. 1 to the 2023 Omnibus Incentive Plan, which updates the evergreen provision for share reserves through 2033. Additionally, shareholders elected two Class III directors and ratified the independent auditor. iBio, Inc. is a biotechnology company focused on developing cell therapies.
iBio released preclinical body-composition data from an eight-week obese non-human primate study evaluating IBIO-610, a potential first-in-class Activin E antibody. When combined with semaglutide, lean mass accounted for only 6% of weight loss compared to 22% with semaglutide alone, while fat comprised 93% of the total weight lost versus 77%. The candidate demonstrated near-complete inhibition of active Activin E and a half-life supporting potential twice-yearly dosing. iBio plans to initiate first-in-human studies in the first half of 2027. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, and other diseases.
iBio, Inc. filed a Form 8-K to update its corporate presentation for investor and analyst meetings. The updated materials highlight the company's pipeline of next-generation antibody therapies targeting obesity and cardiometabolic diseases, specifically IBIO-610 (Activin E), IBIO-800 (Myostatin x Activin A bispecific), and IBIO-600 (Myostatin). Key anticipated milestones include an IND equivalent filing for IBIO-610 in 2H 2026, Phase 1 initiation for IBIO-610 in 1H 2027, and interim Phase 1 data for IBIO-600 in 1Q 2027. The company reported $88.0 million in cash as of June 30, 2026, with a runway extending into Q4 FY 2028. iBio, Inc. operates in the biotechnology industry, developing antibody-based therapeutics for metabolic and cardiovascular conditions.
iBio, Inc. reported financial results for the fiscal year ended June 30, 2026, revealing a net loss of $33.0 million compared to $18.4 million in the prior year. Revenue declined to approximately $0.1 million from $0.4 million, while R&D expenses surged to $19.6 million due to increased consulting costs and development milestones for programs IBIO-610 and IBIO-600. The company recorded a $5.0 million impairment on the IBIO-101 intangible asset but held approximately $88.0 million in cash and investments as of June 30, 2026. Corporate updates included the appointment of Molly Carr, M.D., as Chief Medical Officer and Elizabeth Stoner, M.D., to the Board, alongside progress on clinical trials for its obesity and cardiometabolic pipeline. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, and cardiopulmonary diseases.
iBio, Inc. appointed Molly Carr as Chief Medical Officer effective July 31, 2026. Dr. Carr brings extensive experience from Eli Lilly and GlaxoSmithKline in endocrinology and metabolic diseases. She receives a $470,000 annual base salary with a target bonus of 40% and was granted an inducement award of 430,000 stock options at an exercise price of $1.40 per share. The options vest 25% after one year and the remainder monthly over three years. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, and other diseases.